{
    "clinical_study": {
        "@rank": "50243", 
        "arm_group": [
            {
                "arm_group_label": "Low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Medium dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic\n      (the effect of the investigated drug on the body) response of insulin degludec (insulin 454)\n      with insulin glargine at steady-state conditions in subjects with type 1 diabetes mellitus."
        }, 
        "brief_title": "Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus (as diagnosed clinically) and treated with insulin for at\n             least 12 months\n\n          -  Subject is considered to be generally healthy, except for the underlying diabetes\n             mellitus and related morbidity (such as well controlled hypertension and\n             dyslipidaemia) based on an assessment of medical history, physical examination and\n             clinical laboratory data, as judged by the Investigator\n\n          -  Body Mass Index (BMI) between 18.0 and 28.0 kg/m^2 (both inclusive)\n\n          -  Glycosylated haemoglobin (HbA1c) below or equal to 10.0 % based on central laboratory\n             results\n\n          -  Subject with a daily basal insulin requirement of between  0.2 IU/kg/day and 0.6\n             IU/kg/day will be allowed to participate in the trial. Current total daily treatment\n             with insulin must be less than 1.2 U/kg/day\n\n        Exclusion Criteria:\n\n          -  Known or suspected allergy to trial product(s) or related products\n\n          -  Subject who has participated in any other trials involving investigational products\n             within 3 months preceding the start of dosing\n\n          -  Subject who has donated any blood or plasma in the past month or in excess of 500 mL\n             within the 12 weeks preceding screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "63", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868529", 
            "org_study_id": "NN1250-1876", 
            "secondary_id": "2007-003534-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low dose", 
                    "Medium dose", 
                    "High dose"
                ], 
                "description": "Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.", 
                "intervention_name": "insulin degludec", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low dose", 
                    "Medium dose", 
                    "High dose"
                ], 
                "description": "Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 24, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Single Centre, Double-blind, Two-Period Cross-over, Multiple Dose Trial Comparing the Pharmacodynamic Response of Insulin 454 With Insulin Glargine at Steady-State Conditions in Subjects With Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the glucose infusion rate curve", 
            "safety_issue": "No", 
            "time_frame": "0-24 hours in steady-state"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868529"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area under the serum insulin concentration curve  at steady state", 
            "safety_issue": "No", 
            "time_frame": "0-24 hours after dosing"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}